The Drug Eluting Stent Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The Drug Eluting Stent market has experienced significant growth recently. The market size is projected to rise from $7.63 billion in 2024 to $8.29 billion in 2025, representing a compound annual growth rate (CAGR) of 8.6%.
The Drug Eluting Stent market is projected to grow to a size of $11.37 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 8.2%.
Download Your Free Sample of the 2025 Drug Eluting Stent Market Report and Uncover Key Trends Now!The drivers in the drug eluting stent market are:
• The need for improved treatment options
• Clinical evidence supporting the use of drug eluting stents
• Regulatory approval for the marketing and use of drug eluting stents
• Relevant healthcare economics, guidelines and recommendations.
The drug eluting stent market covered in this report is segmented –
1) By Product: Polymer-Based, Polymer-Free
2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
4) By Application: Coronary Diseases, Peripheral Vascular Diseases
5) By End-User: Hospitals, Specialty Clinic
The trends in the drug eluting stent market are:
• Personalized medicine is becoming a prominent trend in the drug-eluting stent market.
• The market is witnessing a shift towards minimally invasive techniques.
• The integration of emerging healthcare technologies is shaping market trends.
• Development and adoption of next-generation drug formulations is an emerging trend.
The major players in the drug eluting stent market are:
• Johnson & Johnson Services Inc.
North America was the largest region in the drug-eluting stent market in 2023